Antibody-based therapies to fight cancer. Learn How AgilVax’s Technology Fights Cancer. AgilVax Discovers and Develops Targeted Antibody-Based Therapeutics. AgilVax’s lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is overexpressed on numerous tumor types including metastatic breast, colorectal, lung, pancreatic, hepatocellular cancers and glioblastoma. By inhibiting th...
Antibody-based therapies to fight cancer. Learn How AgilVax’s Technology Fights Cancer. AgilVax Discovers and Develops Targeted Antibody-Based Therapeutics. AgilVax’s lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is overexpressed on numerous tumor types including metastatic breast, colorectal, lung, pancreatic, hepatocellular cancers and glioblastoma. By inhibiting the function of xCT, AX09, has the potential to enhance the effectiveness of current therapies, reduce metastatic spread, and make a dramatic improvement in patient survival.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.